{"transactions":[{"id":1404206,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series C Preferred Stock","published_at":"2024-09-18T15:54:57.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":352876,"ownership":{"direct":false,"nature":"Eight Roads Ventures India Healthcare IV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":352876},"source":{"system":"sec-edgar","filing":"0000950170-24-107661","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/318989/000095017024107661/ownership.xml","form_type":"4"}},{"id":1404205,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B Preferred Stock","published_at":"2024-09-18T15:54:57.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":606885,"ownership":{"direct":false,"nature":"Eight Roads Ventures India Healthcare IV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":606885},"source":{"system":"sec-edgar","filing":"0000950170-24-107661","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/318989/000095017024107661/ownership.xml","form_type":"4"}},{"id":1404204,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series Seed Preferred Stock","published_at":"2024-09-18T15:54:57.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":54092,"ownership":{"direct":false,"nature":"Eight Roads Ventures India Healthcare IV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":54092},"source":{"system":"sec-edgar","filing":"0000950170-24-107661","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/318989/000095017024107661/ownership.xml","form_type":"4"}},{"id":1404203,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2024-09-18T15:54:57.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":352876,"ownership":{"direct":false,"nature":"Eight Roads Ventures India Healthcare IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":1013853,"source":{"system":"sec-edgar","filing":"0000950170-24-107661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318989/000095017024107661/ownership.xml","form_type":"4"}},{"id":1404202,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2024-09-18T15:54:57.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":606885,"ownership":{"direct":false,"nature":"Eight Roads Ventures India Healthcare IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":660977,"source":{"system":"sec-edgar","filing":"0000950170-24-107661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318989/000095017024107661/ownership.xml","form_type":"4"}},{"id":1404201,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2024-09-18T15:54:57.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":54092,"ownership":{"direct":false,"nature":"Eight Roads Ventures India Healthcare IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock."}],"balance_after":54092,"source":{"system":"sec-edgar","filing":"0000950170-24-107661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318989/000095017024107661/ownership.xml","form_type":"4"}},{"id":2025705,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A Convertible Preferred Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":false,"shares":624239,"ownership":{"direct":false,"nature":"ERVC Healthcare IV, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":624239},"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025704,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-1 Convertible Preferred Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":false,"shares":494035,"ownership":{"direct":false,"nature":"ERVC Healthcare V, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":494035},"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025703,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B Convertible Preferred Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":false,"shares":7411,"ownership":{"direct":false,"nature":"ERVC Healthcare Advisors IV, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":7411},"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025702,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A+ Convertible Preferred Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":false,"shares":10154,"ownership":{"direct":false,"nature":"ERVC Healthcare Advisors IV, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":10154},"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025701,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A Convertible Preferred Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":false,"shares":71636,"ownership":{"direct":false,"nature":"ERVC Healthcare Advisors IV, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":71636},"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025700,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-1 Convertible Preferred Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":false,"shares":179242,"ownership":{"direct":false,"nature":"Eight Roads Investments"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":179242},"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025699,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B Convertible Preferred Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":false,"shares":452867,"ownership":{"direct":false,"nature":"Eight Roads Investments"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":452867},"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025698,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A+ Convertible Preferred Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":false,"shares":620499,"ownership":{"direct":false,"nature":"Eight Roads Investments"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":620499},"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025697,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A Convertible Preferred Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":false,"shares":4013678,"ownership":{"direct":false,"nature":"Eight Roads Investments"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4013678},"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025696,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Ordinary Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":true,"shares":624239,"ownership":{"direct":false,"nature":"ERVC Healthcare IV, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":624239,"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025695,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Ordinary Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":true,"shares":494035,"ownership":{"direct":false,"nature":"ERVC Healthcare V, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":494035,"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025694,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Ordinary Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":true,"shares":7411,"ownership":{"direct":false,"nature":"ERVC Healthcare Advisors IV, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":89201,"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025693,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Ordinary Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":true,"shares":10154,"ownership":{"direct":false,"nature":"ERVC Healthcare Advisors IV, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":81790,"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025692,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Ordinary Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":true,"shares":71636,"ownership":{"direct":false,"nature":"ERVC Healthcare Advisors IV, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":71636,"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025691,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Ordinary Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":true,"shares":179242,"ownership":{"direct":false,"nature":"Eight Roads Investments"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":5266286,"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025690,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Ordinary Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":true,"shares":452867,"ownership":{"direct":false,"nature":"Eight Roads Investments"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":5087044,"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025689,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Ordinary Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":true,"shares":620499,"ownership":{"direct":false,"nature":"Eight Roads Investments"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":4634177,"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2025688,"issuer":{"id":1222,"kind":"organization","name":"Structure Therapeutics Inc.","symbol":"GPCR"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Ordinary Shares","published_at":"2023-02-09T19:04:59.000Z","date":"2023-02-07","kind":"exercise","acquired":true,"shares":4013678,"ownership":{"direct":false,"nature":"Eight Roads Investments"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares."}],"balance_after":4013678,"source":{"system":"sec-edgar","filing":"0000318989-23-000054","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898923000054/primary_doc.xml","form_type":"4"}},{"id":2533179,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B Preferred Stock","published_at":"2021-10-28T19:57:55.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":2077698,"ownership":{"direct":false,"nature":"Eight Roads Investments"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of  Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of  Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of  Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of  Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":218705},"source":{"system":"sec-edgar","filing":"0000318989-21-000078","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898921000078/primary_doc.xml","form_type":"4"}},{"id":2533178,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2021-10-28T19:57:55.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":218705,"ownership":{"direct":false,"nature":"Eight Roads Investments"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of  Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock."}],"balance_after":218705,"source":{"system":"sec-edgar","filing":"0000318989-21-000078","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898921000078/primary_doc.xml","form_type":"4"}},{"id":3957590,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A Preferred Stock","published_at":"2018-04-25T19:56:29.000Z","date":"2018-04-23","kind":"exercise","acquired":false,"shares":1950777,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":886716},"source":{"system":"sec-edgar","filing":"0000318989-18-000023","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898918000023/primary_doc.xml","form_type":"4"}},{"id":3957589,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2018-04-25T19:56:29.000Z","date":"2018-04-23","kind":"exercise","acquired":true,"shares":886716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 23, 2018, in connection with the completion of the issuer's initial public offering, each 2.2 shares of Series A Preferred Stock converted into 1 share of Common Stock."}],"balance_after":886716,"source":{"system":"sec-edgar","filing":"0000318989-18-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898918000023/primary_doc.xml","form_type":"4"}},{"id":3968844,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B Preferred Stock","published_at":"2018-04-05T16:28:39.000Z","date":"2018-04-03","kind":"exercise","acquired":false,"shares":42931,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":27342},"source":{"system":"sec-edgar","filing":"0000318989-18-000018","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898918000018/primary_doc.xml","form_type":"4"}},{"id":3968843,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A Preferred Stock","published_at":"2018-04-05T16:28:39.000Z","date":"2018-04-03","kind":"exercise","acquired":false,"shares":1744310,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1110932},"source":{"system":"sec-edgar","filing":"0000318989-18-000018","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898918000018/primary_doc.xml","form_type":"4"}},{"id":3968842,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2018-04-05T16:28:39.000Z","date":"2018-04-03","kind":"exercise","acquired":true,"shares":27342,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock."}],"balance_after":1138274,"source":{"system":"sec-edgar","filing":"0000318989-18-000018","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898918000018/primary_doc.xml","form_type":"4"}},{"id":3968841,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2018-04-05T16:28:39.000Z","date":"2018-04-03","kind":"exercise","acquired":true,"shares":1110932,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock."}],"balance_after":1110932,"source":{"system":"sec-edgar","filing":"0000318989-18-000018","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898918000018/primary_doc.xml","form_type":"4"}},{"id":4132591,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":51,"ownership":{"direct":false,"nature":"India Partners II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":51},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":42,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132590,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":34,"ownership":{"direct":false,"nature":"Japan Partners I L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":34},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":41,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132589,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":193,"ownership":{"direct":false,"nature":"Asia Partners III L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":193},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":40,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132588,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":15021,"ownership":{"direct":false,"nature":"FIL Capital Investments (Mauritius) II Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15021},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":39,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132587,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":15068,"ownership":{"direct":false,"nature":"Japan Ventures I L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15068},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":38,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132586,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":54854,"ownership":{"direct":false,"nature":"Asia Ventures III L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":54854},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":37,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132585,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":71875,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":71875},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":36,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132584,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":20,"ownership":{"direct":false,"nature":"India Partners II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":35,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132583,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":13,"ownership":{"direct":false,"nature":"Japan Partners I L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132582,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":77,"ownership":{"direct":false,"nature":"Asia Partners III L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":77},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132581,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":6008,"ownership":{"direct":false,"nature":"FIL Capital Investments (Mauritius) II Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6008},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132580,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":6027,"ownership":{"direct":false,"nature":"Japan Ventures I L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6027},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132579,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":21942,"ownership":{"direct":false,"nature":"Asia Ventures III L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21942},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132578,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":28750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":28750},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132577,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":1008,"ownership":{"direct":false,"nature":"India Partners II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1008},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132576,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":662,"ownership":{"direct":false,"nature":"Japan Partners I L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":662},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132575,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":3755,"ownership":{"direct":false,"nature":"Asia Partners III L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3755},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132574,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":292303,"ownership":{"direct":false,"nature":"FIL Capital Investments (Mauritius) II Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":292303},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132573,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":293204,"ownership":{"direct":false,"nature":"Japan Ventures I L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":293204},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132572,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":1065616,"ownership":{"direct":false,"nature":"Asia Ventures III L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1065616},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132571,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":1397326,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1397326},"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132570,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":51,"ownership":{"direct":false,"nature":"India Partners II L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":1379,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132569,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":20,"ownership":{"direct":false,"nature":"India Partners II L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":1328,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132568,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":1008,"ownership":{"direct":false,"nature":"India Partners II L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":1308,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132567,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":34,"ownership":{"direct":false,"nature":"Japan Partners I L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":906,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132566,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":13,"ownership":{"direct":false,"nature":"Japan Partners I L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":872,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132565,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":662,"ownership":{"direct":false,"nature":"Japan Partners I L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":859,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132564,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":193,"ownership":{"direct":false,"nature":"Asia Partners III L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":5146,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132563,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":77,"ownership":{"direct":false,"nature":"Asia Partners III L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":4953,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132562,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":3755,"ownership":{"direct":false,"nature":"Asia Partners III L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":4876,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132561,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":15021,"ownership":{"direct":false,"nature":"FIL Capital Investments (Mauritius) II Limited"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":400456,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132560,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":6008,"ownership":{"direct":false,"nature":"FIL Capital Investments (Mauritius) II Limited"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":385435,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132559,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":292303,"ownership":{"direct":false,"nature":"FIL Capital Investments (Mauritius) II Limited"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":379427,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132558,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":15068,"ownership":{"direct":false,"nature":"Japan Ventures I L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":401692,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132557,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":6027,"ownership":{"direct":false,"nature":"Japan Ventures I L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":386624,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132556,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":293204,"ownership":{"direct":false,"nature":"Japan Ventures I L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":380597,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132555,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":54854,"ownership":{"direct":false,"nature":"Asia Ventures III L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":1460570,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132554,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":21942,"ownership":{"direct":false,"nature":"Asia Ventures III L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":1405716,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132553,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":1065616,"ownership":{"direct":false,"nature":"Asia Ventures III L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":1383774,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132552,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":71875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":1914833,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132551,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":28750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":1842958,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}},{"id":4132550,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":87462,"kind":"organization","name":"FIL Ltd","position":1,"cik":"0000318989","reported_name":"FIL Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remark 1"}}],"security":"Common Stock","published_at":"2017-12-14T20:20:57.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":1397326,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock."}],"balance_after":1814208,"source":{"system":"sec-edgar","filing":"0000318989-17-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318989/000031898917000042/primary_doc.xml","form_type":"4"}}]}